We can’t show the full text here under this license.
Abstract
Essence
An engineered Un1Cas12f1 variant expanded compact CRISPR targeting and improved editing activity.
Evidence
Bacterial library screening, mammalian cell validation, F0 mouse editing, transcriptional activation, and base-editing platform experiments showed evoCas12f recognized NTNR/NYTR PAMs, raised TTTR-site activity 1.4-fold, and reached up to 91% editing efficiency.
Caveat
The abstract reports platform performance across models rather than therapeutic delivery, off-target safety, or clinical outcome data.
Simplified